

November 26, 2021

Announcement on Acquisition and Retirement of Own Shares

(Acquisition of Own Shares pursuant to the Provisions of Paragraph 2, Article 165 of the Companies Act and Retirement of Own Shares pursuant to the Provisions of Article 178 of the Companies Act)

Osaka, Japan, November 26, 2021 - Ono Pharmaceutical Co., Ltd. (President and CEO: Gyo Sagara; "the Company") today announced that in accordance with Article 370 (resolution by documents instead of resolution by board meetings) of the Companies Act, it has resolved to acquire its own shares under the provisions of Article 156 of the Companies Act, applied by the replacing terms pursuant to the provisions of Paragraph 3, Article 165 of the Companies Act, and retire own shares pursuant to the provisions of Article 178 of the Companies Act.

Particulars

1. Reasons for the acquisition and retirement of own shares

The Company will acquire own shares in order to improve capital efficiency and shareholder return, taking into financial condition, common stock price and other factors.

2.	Contents of the acquisition			
	(1)	Class of shares to be acquired:	Common stock of the Company	
	(2) Total number of shares to be acquired: 11 million shares (maximum)			
			(2.20% of the total outstanding shares excluding	
			own shares)	
	(3)	Total amount of acquisition cost:	¥30.0 billion yen (maximum)	
	(4)	Period of acquisition:	November 29, 2021 to April 28, 2022	
	(5)	Method for acquisition:	Purchase on the Tokyo Stock Exchange	
	(6)	Schedule after acquisition:	All the common stock acquired will be retired.	
3.	3. Contents of the retirement			
	(1)	Class of shares to be retired:	Common stock of the Company	
	(2)	Total number of shares to be retired:	All the common stock acquired in accordance with	
			section 2 above.	
	(3)	Scheduled date of retirement:	June 30, 2022 (planned)	

(Reference) The status of own shares as of September 30, 2021

Total number of shares is	ssued (excluding own shares):	499,226,108 shares
Total number of own sha	res:	29,115,292 shares

Contact: Ono Pharmaceutical Co., Ltd. Corporate Communications <u>public_relations@ono.co.jp</u>